Detail akcie Pacira Pharma online

Business Summary: Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Pacira Biosciences Inc revenues increased 3% to $529.5M. Net income totaled $5.4M vs. loss of $115.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Goodwill impairment decrease from $163.2M (expense) to $0K, Interest income increase of 45% to $20.4M (income), Other.